Oct 29, 2026 04:05PM
Aug 5, 2026 04:05PM
May 5, 2026 04:05PM
Feb 10, 2026 04:05PM
Jan 12, 2026 04:05AM
Jan 11, 2026 04:00PM
Dec 12, 2025 10:31AM GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
Nov 4, 2025 04:27PM
Nov 4, 2025 04:05PM
Jul 28, 2025 04:05PM
May 13, 2025 04:07PM
Feb 11, 2025 04:05PM
Jan 12, 2025 04:00PM
Oct 29, 2024 04:05PM Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Aug 6, 2024 04:05PM
Apr 30, 2024 04:05PM
Feb 6, 2024 04:05PM
Jan 8, 2024 05:25AM
Jan 7, 2024 04:00PM
Sep 12, 2023 08:03AM
Sep 12, 2023 08:00AM Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
Aug 1, 2023 04:05PM
May 9, 2023 04:05PM
Apr 13, 2023 04:11PM
Apr 13, 2023 04:11PM
Mar 20, 2023 07:00AM
Mar 20, 2023 07:00AM
Feb 7, 2023 04:05PM Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Jan 9, 2023 04:58AM
Jan 8, 2023 04:00PM
Jan 4, 2023 09:00AM
Dec 1, 2022 06:23AM
Nov 3, 2022 08:05AM
Nov 3, 2022 08:00AM
Nov 1, 2022 04:08PM Exelixis (EXEL) and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805
Nov 1, 2022 04:07PM
Nov 1, 2022 04:07PM
Nov 1, 2022 04:06PM
Nov 1, 2022 04:05PM
Aug 9, 2022 04:05PM
Jul 7, 2022 12:00AM
Jun 16, 2022 12:00AM Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
May 10, 2022 04:05PM
Apr 13, 2022 04:06PM
Apr 13, 2022 04:05PM
Feb 17, 2022 04:05PM
Jan 10, 2022 05:48AM
Jan 9, 2022 04:00PM
Jan 6, 2022 08:00AM Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor
Nov 2, 2021 04:05PM

1,204,893 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All